Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 8314 results

  1. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TSID10723]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Dupilumab for children with severe atopic dermatitis [TSID10434]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. DV7103 for treating cystinuria in people 6 months and over [TSID10438]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Macitentant–tadalafil for treating pulmonary arterial hypertension [TSID10517]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation